Janux Therapeutics prices $296.5M public offering of common stock and pre-funded warrants

Janux Therapeutics, Inc.

Pricing: 4,440,851 shares at $46.50/share and pre-funded warrants to purchase 1,935,483 shares at $46.499.
Gross proceeds ~$296.5M, up from initial $175M offering; underwriters have 30-day option for 956,450 shares.
Proceeds to fund clinical pipeline development and general corporate purposes; close expected March 4, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.